EcoDrugPlus

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSG00000166483
Gene: WEE1
Gene Synonyms: WEE1A
1 APIs:
18 Enzyme and pathways 7 Cross references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSG00000176105
Gene: YES1
Gene Synonyms: C-YES,HST441,YES
1 APIs:
46 Enzyme and pathways 7 Cross references
258 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSG00000087085
Gene: ACHE
Gene Synonyms: YT
19 APIs:
11 Enzyme and pathways 9 Cross references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Activin A Receptor Like Type 1

Ensembl ID : ENSG00000139567
Gene: ACVRL1
Gene Synonyms: ACVRLK1,ALK1,HHT,HHT2,ORW2
2 APIs:
3 Enzyme and pathways 9 Cross references
358 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Activin A Receptor Type 2b

Ensembl ID : ENSG00000114739
Gene: ACVR2B
Gene Synonyms: ACTR-IIB
1 APIs:
7 Enzyme and pathways 8 Cross references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine A1 Receptor

Ensembl ID : ENSG00000163485
Gene: ADORA1
Gene Synonyms: RDC7
15 APIs:
8 Enzyme and pathways 7 Cross references
275 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine A2a Receptor

Ensembl ID : ENSG00000128271
Gene: ADORA2A
Gene Synonyms: ADORA2,RDC8
19 APIs:
15 Enzyme and pathways 7 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine A2b Receptor

Ensembl ID : ENSG00000170425
Gene: ADORA2B
Gene Synonyms:
5 APIs:
16 Enzyme and pathways 7 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine A3 Receptor

Ensembl ID : ENSG00000282608
Gene: ADORA3
Gene Synonyms: A3AR,AD026
3 APIs:
8 Enzyme and pathways 8 Cross references
273 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adenosine Deaminase

Ensembl ID : ENSG00000196839
Gene: ADA
Gene Synonyms: ADA1
2 APIs:
11 Enzyme and pathways 10 Cross references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Alpha 1a

Ensembl ID : ENSG00000120907
Gene: ADRA1A
Gene Synonyms: ADRA1C,ADRA1L1
35 APIs:
9 Enzyme and pathways 7 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Alpha 1b

Ensembl ID : ENSG00000170214
Gene: ADRA1B
Gene Synonyms:
29 APIs:
9 Enzyme and pathways 7 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).